In order to distribute an authorized generic version of metoprolol succinate (25 mg dosage strength) in the United States, AstraZeneca (NYSE: AZN) entered into a supply and distribution agreement with Par Pharmaceutical (11855577).
However, the said agreement does not affect the availability of AstraZeneca's branded version of metoprolol succinate, TOPROL-XL®, which will be continuously manufactured by AstraZeneca for availability in the United States.
A 25 mg version of metoprolol succinate was launched in the United States yesterday by Eon Labs, part of Sandoz. The 25 mg dose accounts for an estimated 20 percent of AstraZeneca's TOPROL-XL sales in the US.
TOPROL-XL® is the world's leading cardioselective beta-blocker for hypertension, angina pectoris, heart failure, disturbances of cardiac rhythm including especially supraventricular tachycardia, maintenance treatment after myocardial infarction and functional heart disorders with palpitations and for migraine prophylaxis.
Find more details from the press release.
Comment Preview